Research programme: small molecule therapeutics - Gotham Therapeutics
Latest Information Update: 26 Dec 2023
At a glance
- Originator Gotham Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Methyltransferase inhibitors; RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- Discontinued Autoimmune disorders; Neurodegenerative disorders
Most Recent Events
- 26 Dec 2023 Preclinical development is ongoing in Cancer in USA (858 Therapeutics pipeline; December 2023)
- 26 Dec 2023 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route) (858 Therapeutics website, December 2023)
- 26 Dec 2023 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route) (858 Therapeutics website, December 2023)